In transmyocardial laser revascularization, a small left thoracotomy incision is made at the fifth rib. The surgeon dissects until adequate exposure of the heart is made, and the laser can be used. The areas to be lasered are identified, and treatment begins. As each laser beam penetrates the myocardium, a flash of bubbles can be seen on echocardiogram exiting the left ventricular outflow tract, which confirms adequate channeling. After revascularization, the mitral valve is inspected for any damage to papillary muscle or leaflets. This case report focuses on a new laser procedure that creates channels in the heart that promote angiogenesis and reestablish blood flow. A 47-year-old man presented for this surgery after having previous coronary artery bypass surgery. He had worsening angina and was not recommended for repeat bypass surgery because of his diffuse disease. Transmyocardial laser revascularization was offered as an alternative to medical therapy. Complications reported include dysrhythmia, bleeding, congestive heart failure, mitral valve damage, low cardiac output syndrome, and death. Many patients note substantial anginal relief after a few weeks. Transmyocardial laser revascularization gives an alternative to those with intractable angina and generally offers an improvement in quality of life.
Download full-text PDF |
Source |
---|
Cureus
May 2024
Department of Research, NFSci, LLC, Tucson, USA.
Background Coronary artery disease (CAD) is a global health burden, contributing to mortality and morbidity. A proportion of patients with CAD suffer from diffuse CAD, where conventional revascularization techniques such as percutaneous coronary intervention and coronary artery bypass grafting (CABG) may be insufficient to adequately restore myocardial perfusion. Transmyocardial revascularization (TMR) uses a laser to create microscopic channels in the myocardium, inducing inflammation, angiogenesis, and neovascularization to improve perfusion to ischemic regions.
View Article and Find Full Text PDFCurr Pharm Des
September 2023
1st Cardiology Department, "Hippokration" General Hospital, University of Athens Medical School, Athens, Greece.
Stem Cell Rev Rep
April 2023
Department of Cardiothoracic Surgery, University of Kentucky, Lexington, KY, USA.
Objective: We tested the hypothesis that targeted TMLR combined with intramyocardial injection of autologous CD 133 progenitor cells is safe and feasible in patients with chronic ischemic cardiomyopathy (ICM) and no revascularization options.
Methods: Eight male patients (age 62 ± 2.4 years) with multivessel severe ischemic heart disease and no revascularization options were enrolled.
J Lasers Med Sci
September 2021
Department of Cardiology, Taleghani Hospital, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!